Seelos Therapeutics Shares Outstanding 2010-2022 | SEEL

Seelos Therapeutics shares outstanding from 2010 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Seelos Therapeutics Annual Shares Outstanding
(Millions of Shares)
2021 91
2020 45
2019 20
2018 3
2017 0
2016 0
2015 0
2014 0
2013 0
2012 0
2011 0
2010 0
2009 0
Seelos Therapeutics Quarterly Shares Outstanding
(Millions of Shares)
2022-06-30 106
2022-03-31 106
2021-12-31 91
2021-09-30 102
2021-06-30 88
2021-03-31 69
2020-12-31 45
2020-09-30 47
2020-06-30 44
2020-03-31 34
2019-12-31 20
2019-09-30 24
2019-06-30 21
2019-03-31 9
2018-12-31 3
2018-09-30 3
2018-06-30 3
2018-03-31 3
2017-12-31 0
2017-09-30 0
2017-06-30 0
2017-03-31 0
2016-12-31 0
2016-09-30 0
2016-06-30 0
2016-03-31 0
2015-12-31 0
2015-09-30 0
2015-06-30 0
2015-03-31 0
2014-12-31 0
2014-09-30 0
2014-06-30 0
2014-03-31 0
2013-12-31 0
2013-09-30 0
2013-06-30 0
2013-03-31 0
2012-12-31 0
2012-09-30 0
2012-06-30 0
2012-03-31 0
2011-12-31 0
2011-09-30 0
2011-06-30 0
2011-03-31 0
2010-12-31 0
2010-09-30 0
2010-06-30 0
2010-03-31 0
2009-12-31 0
2009-09-30 0
2009-06-30 0
2009-03-31 0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.098B $0.000B
Seelos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the development and advancement of novel therapeutics to address unmet medical needs for central nervous system disorders. The company's product pipeline consists of SLS-002, SLS-006, SLS-008, SLS-010 and SLS-012 which are in clinical stage. Seelos Therapeutics Inc., formerly known as Apricus Biosciences Inc., is based in New York, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.286B 9.60
GSK (GSK) United Kingdom $71.707B 8.61
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.077B 18.55
Biohaven Pharmaceutical Holding (BHVN) United States $10.582B 0.00
Ginkgo Bioworks Holdings (DNA) United States $6.645B 0.00
Arcus Biosciences (RCUS) United States $1.982B 38.68
Myovant Sciences (MYOV) United Kingdom $1.693B 0.00
Emergent Biosolutions (EBS) United States $1.465B 8.49
Zymeworks (ZYME) Canada $0.405B 0.00
Enzo Biochem (ENZ) United States $0.132B 0.00
Gelesis Holdings (GLS) United States $0.101B 0.00
Ambrx Biopharma (AMAM) United States $0.099B 0.00
SQZ Biotechnologies (SQZ) United States $0.096B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00